Amylin and GLP-1 combination
CagriSema
CagriSema, once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg, gave a mean body-weight change of -20.4% at 68 weeks against -3.0% on placebo in REDEFINE 1, in adults without diabetes (treatment-policy estimand).1
CagriSema after one dose: 50% at ~170 h, 25% at 340 h, 12.5% at 510 h.
Drawn from the half-life in the app's model, ~170 h. The model's figures
- Compound
- CagriSema
- Symbol
- CS
- Family
- GLP-1 and incretin
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg, a long-acting amylin analogue, and semaglutide 2.4 mg, a GLP-1 receptor agonist, given as a once-weekly subcutaneous injection in the trials described here.2 Novo Nordisk's press release of 18 December 2025 announced a New Drug Application to the US Food and Drug Administration for CagriSema and states that "CagriSema is not approved in the US or EU".2 The app grades the evidence for CagriSema as emerging. REDEFINE 1, REDEFINE 2, the phase 2 trial and the phase 1b trial described below were each funded by Novo Nordisk.1,3,4,5 A ClinicalTrials.gov search for CagriSema returned 32 studies, and every one of the first 20 listed Novo Nordisk A/S as sponsor. Published trials of the combination include a phase 1b trial, a phase 2 trial in type 2 diabetes and two phase 3a trials, and the sections below give single-component arm results only where the retrieved sources report them.5,4,1,3
How it works
Sources in this part
The phase 1b trial describes cagrilintide as "a long-acting amylin analogue" and semaglutide as "a glucagon-like peptide-1 analogue".5 Novo Nordisk's press release says the combination pairs the amylin analogue with semaglutide "to target complementary obesity-related pathways".2 The Wegovy label, which covers semaglutide alone, states that semaglutide "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor".6 The same label states that "GLP-1 is a physiological regulator of appetite and caloric intake" and that semaglutide's effects "are likely mediated by affecting appetite".6 No label for cagrilintide or for CagriSema was identified, so the amylin-side mechanism is described here only by the trial authors' wording above. In a secondary analysis of REDEFINE 1, the authors write that "pleiotropic effects of GLP-1 and amylin may play a role in the BP-lowering effects of CagriSema", a suggestion rather than a tested mechanism.7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~170 h
- Bioavailability
- 85%
- Typical dose
- 0.5–4.8 mg/week
- Route
- SubQ
- Time to peak
- ~24 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report; the sources give figures for each component, not for the combination as a single product.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 7.1 days (170 hours) | In the phase 1b trial, cagrilintide 0·16-4·5 mg had a half-life of 159-195 h and semaglutide 2·4 mg a half-life of 145-165 h; the Wegovy label gives semaglutide an elimination half-life of approximately 1 week5,6 |
| Time to peak | About 24 hours | Median time to maximum concentration of 24-72 h for cagrilintide and 12-24 h for semaglutide 2·4 mg in the phase 1b trial; "1 to 3 days post dose" for semaglutide on the Wegovy label5,6 |
| Bioavailability | 85% | 89% for semaglutide alone after subcutaneous administration on the Wegovy label; no figure for cagrilintide or for the combination was identified in the sources retrieved6 |
| Exposure | Not given | AUC0-168 h of 926 to 24 271 nmol × h/L for cagrilintide 0·16-4·5 mg and 12 757 to 15 305 nmol × h/L for semaglutide 2·4 mg5 |
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once-weekly injection in REDEFINE 11.
An illustration from a pharmacokinetic model using a half-life of 170 hours (7.08 days). It is not a measured level or a suggested dose.
The phase 1b trial enrolled "individuals aged 18-55 years with a body-mass index 27·0-39·9 kg/m2 and who were otherwise healthy" at a single centre in the USA, so these figures come from a narrow group.5
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Enebo and colleagues, phase 1b, Lancet 20215 | Randomised, placebo-controlled, multiple-ascending-dose trial at a single US centre; funded by Novo Nordisk A/S5 | 96 randomised, 95 exposed; aged 18-55 years, BMI 27·0-39·9 kg/m2, otherwise healthy5 | Cagrilintide 0·16 to 4·5 mg or placebo, each with semaglutide 2·4 mg once weekly subcutaneously; co-escalated over 16 weeks, 4 weeks at target dose, 5 weeks of follow-up5 | Primary end point was the number of treatment-emergent adverse events: 566 adverse events in 92 participants (69 of 71 on cagrilintide, 23 of 24 on placebo), 37% gastrointestinal. Exploratory weight end point at week 20, without lifestyle interventions: weight fell 17·1% with cagrilintide 2·4 mg and 9·8% with pooled placebo, both with semaglutide 2·4 mg (estimated difference -7·4%, 95% CI -11·2 to -3·5)5 |
| Frias and colleagues, phase 2, Lancet 20234 | 32-week, multicentre, double-blind trial at 17 US sites; funded by Novo Nordisk4 | 92 adults with type 2 diabetes and BMI of 27 kg/m2 or higher on metformin with or without an SGLT2 inhibitor; mean age 58 years4 | CagriSema (n=31), semaglutide (n=31) or cagrilintide (n=30), all escalated to 2·4 mg once weekly subcutaneously; 32 weeks4 | HbA1c fell 2·2 percentage points with CagriSema, 1·8 with semaglutide and 0·9 with cagrilintide; greater than cagrilintide, not significantly different from semaglutide (p=0·075); weight fell 15·6%, 5·1% and 8·1%4 |
| Garvey and colleagues, REDEFINE 1, New England Journal of Medicine 20251 | Phase 3a, 68-week, double-blind, placebo-controlled and active-controlled trial; funded by Novo Nordisk1 | 3417 adults without diabetes with BMI of 30 or higher, or 27 or higher with at least one obesity-related complication1 | Cagrilintide 2.4 mg with semaglutide 2.4 mg (n=2108), semaglutide 2.4 mg (n=302), cagrilintide 2.4 mg (n=302) or placebo (n=705), once weekly subcutaneously, plus lifestyle interventions; 68 weeks1 | Treatment-policy weight change of -20.4% with the combination against -3.0% with placebo (difference -17.3 percentage points, 95% CI -18.1 to -16.6; P<0.001); gastrointestinal adverse events in 79.6% against 39.9%1 |
| Davies and colleagues, REDEFINE 2, New England Journal of Medicine 20253 | Phase 3a, double-blind, randomised, placebo-controlled trial in 12 countries; funded by Novo Nordisk3 | 1206 adults with BMI of 27 or more, HbA1c of 7 to 10% and type 2 diabetes3 | Cagrilintide-semaglutide 2.4 mg each (n=904) or placebo (n=302), once weekly subcutaneously, with lifestyle intervention; 68 weeks3 | Treatment-policy weight change of -13.7% against -3.4% with placebo (difference -10.4 percentage points, 95% CI -11.2 to -9.5; P<0.001); HbA1c of 6.5% or less in 73.5% against 15.9%; gastrointestinal adverse events in 72.5% against 34.4%3 |
| Verma and colleagues, REDEFINE 1 blood pressure analysis, Hypertension 20267 | Secondary and post hoc analyses of REDEFINE 1, focusing on the CagriSema and placebo groups; funded by Novo Nordisk7 | The 3417 randomised REDEFINE 1 participants (2108 CagriSema, 705 placebo), with a subgroup of 167 with resistant hypertension at baseline (CagriSema n=98, semaglutide n=13, cagrilintide n=12, placebo n=44)7 | Cagrilintide-semaglutide 2.4 mg/2.4 mg against placebo, 68 weeks7 | Systolic blood pressure -10.9 against -2.8 mm Hg and diastolic -5.4 against -1.7 mm Hg (trial-product estimand, on-treatment period); in resistant hypertension, targets reached by 42.0% against 29.3% (odds ratio 1.7, 95% CI 0.7 to 4.4)7 |
Deeper analysis: REDEFINE 1
Garvey and colleagues, with the REDEFINE 1 Study Group, reported REDEFINE 1 in the New England Journal of Medicine in 2025.1 The coprimary end points were "the relative change in body weight and a reduction of 5% or more in body weight from baseline to week 68 with cagrilintide-semaglutide as compared with placebo".1 Reductions of 20% or more, 25% or more and 30% or more were "confirmatory secondary end points", and effect estimates used the treatment-policy estimand, described as "consistent with the intention-to-treat principle".1 The PubMed record reports that participants on the combination were more likely than those on placebo to reach reductions of 5% or more, 20% or more, 25% or more and 30% or more (P<0.001 for all comparisons).1 Novo Nordisk's press release adds a trial-product estimand, which assumes all patients stayed on treatment, giving 22.7% weight loss against 2.3% with placebo, against the 20.4% and 3.0% of the treatment-policy estimand.2 In the secondary blood pressure analysis, 61.5% of participants on the combination reached weight loss of 20% or more, against 29.5% on semaglutide and 15.2% on cagrilintide.7 Gastrointestinal adverse events affected 79.6% on the combination and 39.9% on placebo, which the authors call "mainly transient and mild-to-moderate in severity".1 The company reports that adverse events led to discontinuation in 5.9% on CagriSema and 3.5% on placebo, and that nausea affected 55% against 12.6%, constipation 30.7% against 11.6% and vomiting 26.1% against 4.1%.2 In the blood pressure analysis, hypotension was reported in 38 (1.8%) on CagriSema and 3 (0.4%) on placebo.7 In the resistant hypertension subgroup of 167 (CagriSema n=98, semaglutide n=13, cagrilintide n=12, placebo n=44), the difference between CagriSema and placebo in the share reaching blood pressure targets (42.0% against 29.3%) had an odds ratio of 1.7 with a 95% confidence interval of 0.7 to 4.4, which includes 1.7 The registry entry names Novo Nordisk A/S as lead sponsor and, in the version retrieved, lists the status as active, not recruiting, with an extension in which participants receive no study medicine.8 Funding came from Novo Nordisk, and the affiliation list places three authors (Osorto Contreras, Winning Lehmann and Zeuthen) at Novo Nordisk, Søborg, Denmark.1 In the blood pressure analysis, Garvey's disclosure lists work as a consultant on advisory boards for several companies including Novo Nordisk, and three authors are described as "employees and shareholders with Novo Nordisk A/S".7 Only the PubMed record of the main REDEFINE 1 paper was retrievable, because it is not in PubMed Central, so its authors' own limitations section is not quoted here.1 The authors of the blood pressure analysis state that "Limitations include a predominantly female and White population" and that "the cuff size was not specified, and group circumference was not measured, both of which can affect the measurement of BP".7
Deeper analysis: REDEFINE 2
Davies and colleagues reported REDEFINE 2 in the New England Journal of Medicine in 2025, in adults with type 2 diabetes.3 The two primary end points were "the percent change in body weight and the percentage of patients with a weight reduction of at least 5%", with glycemic measures and safety as additional end points.3 Weight changed by -13.7% on the combination against -3.4% on placebo, and reductions of at least 10%, 15% and 20% were also more frequent on the combination (P<0.001 for the 20% comparison).3 The PubMed record gives HbA1c of 6.5% or less in 73.5% against 15.9%, and gives no comparison with a semaglutide-alone or cagrilintide-alone arm, because the trial had only two arms.3 Gastrointestinal adverse events occurred in 72.5% on the combination and 34.4% on placebo, "most of which were transient and mild or moderate in severity".3 Novo Nordisk's press release reports discontinuation due to adverse events in 8.4% on CagriSema and 3% on placebo in REDEFINE 2.2 The registry entry lists the study as completed with Novo Nordisk A/S as lead sponsor.9 Funding came from Novo Nordisk, and the affiliations place Broholm, Eliasen and Lyndgaard at Novo Nordisk, Søborg, Denmark.3 The PubMed record retrieved for REDEFINE 2 is not in PubMed Central and contains no limitations section, so the authors' own limitations are not quoted here.3
Deeper analysis: the phase 2 trial in type 2 diabetes
Frias and colleagues (Velocity Clinical Research, with Novo Nordisk and university authors) reported the phase 2 trial in The Lancet in 2023.4 The primary end point was change in HbA1c, with bodyweight, fasting plasma glucose, continuous glucose monitoring parameters and safety as secondary end points.4 HbA1c change with CagriSema was greater than with cagrilintide (estimated difference -1·3 percentage points, 95% CI -1·7 to -0·8) but, in the authors' words, "not versus semaglutide (-0·4 percentage points [-0·8 to 0·0]; p=0·075)".4 Adverse events were reported by 21 (68%) on CagriSema, 22 (71%) on semaglutide and 24 (80%) on cagrilintide, and "No fatal adverse events were reported".4 The registry results list no serious adverse events among 31 participants on the combination, 4 of 30 on cagrilintide with placebo and 2 of 31 on semaglutide with placebo.10 The authors write that the data "support further investigation of CagriSema in this population in longer and larger phase 3 studies".4 Funding came from Novo Nordisk, and the conflict of interest statement says Deenadayalan, Erichsen and Macura "are employed at Novo Nordisk and are stockholders of Novo Nordisk shares".4 The same statement lists research funding paid to the institution from Novo Nordisk for Frias, Knop and Lingvay, and consulting or advisory work for Novo Nordisk for Frias, Knop and Davies.4 The PubMed record retrieved does not include a limitations section, so the authors' own stated limitations are not quoted here.4
Deeper analysis: the phase 1b trial
Enebo and colleagues reported the phase 1b trial in The Lancet in 2021, with a primary end point of "number of treatment-emergent adverse events from baseline to end of follow-up".5 Weight reductions at week 20 were 15·7% with cagrilintide 1·2 mg and 17·1% with 2·4 mg against 9·8% with pooled placebo, and 15·4% with 4·5 mg against 8·0% with matched placebo, all alongside semaglutide 2·4 mg.5 Of 566 adverse events in 92 participants, 69 (97%) of 71 on cagrilintide and 23 (96%) of 24 on placebo had at least one, and "Most adverse events were mild to moderate in severity".5 The authors conclude that "Future larger and longer trials are needed to fully assess the efficacy and safety of this treatment combination".5 Funding came from Novo Nordisk A/S, four authors are described as employees and shareholders of Novo Nordisk A/S, and the principal investigator "received sponsorship from Novo Nordisk".5 The same statement describes Rubino as a consultant, advisory board member, speaker, clinical investigator for, and shareholder of Novo Nordisk.5
Doses reported in studies and on labels
The app's typical dose range is 0.5 to 4.8 mg per week; the phase 2 trial and both REDEFINE trials gave cagrilintide and semaglutide together, each at a maintenance dose of 2.4 mg once weekly, which is 4.8 mg of the two combined, while the phase 1b trial gave cagrilintide 0·16 to 4·5 mg with semaglutide 2·4 mg.10,5 None of the records retrieved gives 0.5 mg per week as a typical dose of the combination.
| Source | Dose and route | Duration and comparator | People | Estimand or note |
|---|---|---|---|---|
| REDEFINE 11 | Cagrilintide 2.4 mg with semaglutide 2.4 mg, once weekly, subcutaneous | 68 weeks; against semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo | n=2108 combination, 302, 302 and 705 | Treatment-policy estimand for the effect estimates |
| REDEFINE 23 | Cagrilintide-semaglutide 2.4 mg each, once weekly, subcutaneous | 68 weeks; against placebo | n=904 combination, 302 placebo | Treatment-policy estimand |
| Phase 2 trial10 | Escalation from 0.25 mg once weekly: 0.5 mg (weeks 5 to 8), 1.0 mg (weeks 9 to 12), 1.7 mg (weeks 13 to 16), 2.4 mg (weeks 17 to 32), subcutaneous | 32 weeks; against semaglutide 2.4 mg and cagrilintide 2.4 mg | n=31, 31 and 30 | Registry description of the combination arm |
| Phase 1b trial5 | Cagrilintide 0·16 to 4·5 mg with semaglutide 2·4 mg, once weekly, subcutaneous | 16 weeks of co-escalation, 4 weeks at target dose, 5 weeks of follow-up; against placebo with semaglutide 2·4 mg | n=96 randomised | Safety, pharmacokinetic and exploratory weight end points |
| Wegovy label (semaglutide alone)6 | Initiation at 0.25 mg once weekly for 4 weeks, then titration every 4 weeks to a maintenance dosage, subcutaneous injection | Label schedule for the semaglutide product, with a reduced calorie diet | Adults and pediatric patients aged 12 years and older with obesity, and adults with overweight and a weight-related comorbid condition | Label for semaglutide only; no label for CagriSema was identified |
Side effects reported
In REDEFINE 1, gastrointestinal adverse events affected 79.6% on the combination and 39.9% on placebo, and in REDEFINE 2 they affected 72.5% and 34.4%.1,3 Novo Nordisk reports, for REDEFINE 1, nausea in 55% against 12.6%, constipation in 30.7% against 11.6% and vomiting in 26.1% against 4.1%.2 The same release gives discontinuation due to adverse events as 5.9% against 3.5% in REDEFINE 1 and 8.4% against 3% in REDEFINE 2.2 In the 92-person phase 2 trial, adverse events occurred in 68% on CagriSema, 71% on semaglutide and 80% on cagrilintide, with no level 2 or 3 hypoglycaemia and no fatal adverse events.4 The Wegovy label lists, for semaglutide alone, most common adverse reactions of 5% or more including nausea, diarrhea, vomiting, constipation and abdominal pain, and its warnings state that "In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures" while human relevance "has not been determined".6 Those label statements apply to semaglutide, and no label for the combination was identified.
Bloodwork and markers
Sources in this part
The app lists HbA1c, fasting glucose and heart rate as markers to monitor. In REDEFINE 2, 73.5% of adults with type 2 diabetes on the combination had an HbA1c of 6.5% or less at week 68 against 15.9% on placebo.3 In the phase 2 trial, HbA1c fell by 2·2 percentage points and fasting plasma glucose by 3·3 mmol/L with CagriSema over 32 weeks.4 In REDEFINE 1, systolic blood pressure changed by -10.9 mm Hg on the combination and -2.8 mm Hg on placebo (trial-product estimand, on-treatment period), and among participants receiving antihypertensive medication, 39.6% on CagriSema decreased or stopped treatment against 27.4% on semaglutide, 27.6% on cagrilintide and 18.8% on placebo (treatment-policy estimand).7 The authors report that a mediation analysis found "a change in body weight was the primary contributing factor (72%) to the reduction in SBP".7 None of the records retrieved reports a heart rate result for the combination. For semaglutide alone, the Wegovy label states that treatment "was associated with increases in resting heart rate", with mean increases of 1 to 4 beats per minute in adults against placebo in weight-reduction trials.6
Regulatory and anti-doping status
Sources in this part
Novo Nordisk's press release of 18 December 2025 says the New Drug Application seeks use with a reduced-calorie diet and increased physical activity in adults with obesity, or overweight with at least one weight-related comorbid condition.2 The release states that "The FDA is expected to review the CagriSema application in 2026" and that CagriSema "is not approved in the US or EU".2 A web search on 16 November 2026 did not identify an FDA decision, approval or complete response letter, and the company release is the latest primary statement retrieved. A DailyMed search for the two components together returned no label. In the text of the WADA 2026 Prohibited List retrieved, a search for semaglutide, cagrilintide, GLP-1 and amylin found no match, so the list does not name CagriSema or its components.11 No separate WADA statement on CagriSema was identified.
What is not known
Sources in this part
The REDEFINE 1 registry entry describes an extension of about 2 years in which participants stop study medicine and are followed for body weight, so longer-term results are not in the records retrieved.8 Novo Nordisk lists REDEFINE 3, "an event-driven cardiovascular outcomes phase 3 trial", among trials underway, and no cardiovascular outcome result for the combination was identified.2 The blood pressure authors list a predominantly female and White study population as a limitation.7 The trials retrieved all list Novo Nordisk as funder, and no trial of CagriSema run by an independent sponsor was identified in the first 20 registry records returned. The app's figures for bioavailability, absorption rate constant, volume of distribution and compartment model have no matching figure in the sources retrieved for the combination.
Frequently asked questions
What is the half-life of CagriSema?
How long does CagriSema take to reach its peak level?
What is the bioavailability of CagriSema?
The app lists 85%, while the Wegovy label gives 89% for semaglutide alone after subcutaneous administration.6 No figure for cagrilintide or for the combination was identified in the sources retrieved.
Is CagriSema FDA approved?
Novo Nordisk's press release of 18 December 2025 states that "CagriSema is not approved in the US or EU" and that a New Drug Application had been submitted to the FDA.2 A web search on 16 November 2026 did not identify an FDA decision.
How much weight did people lose on CagriSema in trials?
Has CagriSema been compared with semaglutide alone?
Yes, REDEFINE 1 and the phase 2 trial each had a semaglutide 2.4 mg arm.1,4 In the phase 2 trial, weight fell 15·6% on CagriSema and 5·1% on semaglutide, while the HbA1c difference against semaglutide was not significant (p=0·075).4 In the REDEFINE 1 blood pressure analysis, 61.5% on CagriSema, 29.5% on semaglutide and 15.2% on cagrilintide reached weight loss of 20% or more.7
What side effects were reported with CagriSema in trials?
Is CagriSema banned by WADA?
The WADA 2026 Prohibited List text retrieved does not name semaglutide, cagrilintide, GLP-1 or amylin agents.11 No separate WADA statement on CagriSema was identified.
Guides, tools and comparisons
References
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med 2025;393(7):635-647. PMID 40544433
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. Press release, 18 December 2025. Novo Nordisk press release
- Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med 2025;393(7):648-659. PMID 40544432
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a phase 2 trial. Lancet 2023;402(10403):720-730. PMID 37364590
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a phase 1b trial. Lancet 2021;397(10286):1736-1748. PMID 33894838
- Novo Nordisk. Wegovy (semaglutide) injection and tablets. US prescribing information (semaglutide alone), DailyMed. DailyMed label
- Verma S, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension 2026. PMC12822771
- ClinicalTrials.gov. NCT05567796, REDEFINE 1. Sponsor: Novo Nordisk A/S. NCT05567796
- ClinicalTrials.gov. NCT05394519, REDEFINE 2. Sponsor: Novo Nordisk A/S. NCT05394519
- ClinicalTrials.gov. NCT04982575, phase 2 trial of cagrilintide with semaglutide in type 2 diabetes. Sponsor: Novo Nordisk A/S. NCT04982575
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list